Literature DB >> 2221872

In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

N Khardori1, A Reuben, B Rosenbaum, K Rolston, G P Bodey.   

Abstract

The susceptibilities of 45 clinical and 3 environmental isolates of Xanthomonas maltophilia to 14 antimicrobial agents was determined by broth microdilution. The newer quinolones PD117596, PD117558, PD127391, A-56620, amifloxacin, and fleroxacin were the most active agents tested, with 70 to 99% of isolates being susceptible to these agents. All isolates were resistant to trospectomycin. The new aminoglycosides SCH24120 and SCH22591 were active against 12 and 1% of isolates, respectively.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2221872      PMCID： PMC171884          DOI： 10.1128/AAC.34.8.1609

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro evaluation of A-56619 and A-56620, two new quinolones.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

2.  In vitro susceptibility of Pseudomanas cepacia and Pseudomonas maltophilia to trimethoprim and trimethoprim-sulfamethoxazole.

Authors:  M R Moody; W M Young
Journal:  Antimicrob Agents Chemother       Date:  1975-06       Impact factor: 5.191

3.  In-vitro susceptibility of Pseudomonas species to fifteen antimicrobial agents.

Authors:  K V Rolston; E A Anaissie; G P Bodey
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

4.  In vitro antibiotic susceptibility of pseudomonads other than Pseudomonas aeruginosa recovered from cancer patients.

Authors:  M R Moody; V M Young; D M Kenton
Journal:  Antimicrob Agents Chemother       Date:  1972-11       Impact factor: 5.191

5.  Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

Authors:  T P Felegie; V L Yu; L W Rumans; R B Yee
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

6.  Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature.

Authors:  J J Zuravleff; V L Yu
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

7.  Susceptibilities of Pseudomonas species to tetracycline, minocycline, gentamicin, and tobramycin.

Authors:  R C Tilton; O Steingrimsson; R W Ryan
Journal:  Am J Clin Pathol       Date:  1978-04       Impact factor: 2.493

8.  In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.

Authors:  K Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

9.  Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

Authors:  A J Morrison; K K Hoffmann; R P Wenzel
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

10.  Synergistic effect of combinations of sulfamethoxazole, trimethoprim, and colistin against Pseudomonas maltophilia and Pseudomonas cepacia.

Authors:  C E Nord; T Wadström; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191
View more
  19 in total

1.  Antimicrobial activities of gatifloxacin against nosocomial isolates of Stenotrophomonas maltophilia measured by MIC and time-kill studies.

Authors:  M L Cohn; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Pseudo-, Xantho-, and now Stenotrophomonas maltophilia: New kid on the block.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1996-03

3.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors:  S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

5.  In vitro activity of ofloxacin, ciprofloxacin, and cefoperazone alone and in combination against Xanthomonas maltophilia.

Authors:  T A Ristow; L R Peterson; J B Kahn
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 6.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

7.  Stenotrophomonas maltophilia induced post-cataract-surgery endophthalmitis: Outbreak investigation and clinical courses of 26 patients.

Authors:  S Horster; L Bader; U Seybold; I Eschler; K G Riedel; J R Bogner
Journal:  Infection       Date:  2008-12-05       Impact factor: 3.553

8.  Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

Authors:  G A Pankuch; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.